68158 Federal Register / Vol. 65, No. 220 / Tuesday, November 14, 2000 / Notices

1See USTR Federal Register notice of November

1, 2000 (65 FR 65370) for article description.

to the HTS subheadings 1 listed below

imported from India:

7113.19.25 7418.19.10

7113.19.29 9405.50.30

7113.19.50

With respect to the competitive need

limit in section 503(c)(2)(A)(i)(I) of the

1974 Act, the Commission, as requested,

will use the dollar value limit of

$95,000,000.

As requested by USTR, the

Commission will seek to provide its

advice not later than February 6, 2001.

EFFECTIVE DATE: November 6, 2000.

FOR FURTHER INFORMATION CONTACT: (1)

Project Manager, Eric Land (202–205–

3349), (2) Deputy Project Manager,

Cynthia B. Foreso (202–205–3348). The

above persons are in the Commission’s

Office of Industries. For information on

legal aspects of the investigation contact

William Gearhart of the Commission’s

Office of the General Counsel at 202–

205–3091.

Background

The subject articles the product of

India are currently ineligible for dutyfree treatment under the GSP program

because imports from India exceed the

competitive need limits. The USTR

letter noted that as a result of a White

House Initiative with India, the Trade

Policy Staff Committee (TPSC) recently

announced in the Federal Register the

initiation of a review to consider

modification of the GSP with respect to

such products imported from India.

Modifications to the GSP which may

result from this review will be

announced in the spring of 2001.

Public Hearing

A public hearing in connection with

this investigation is scheduled to begin

at 9:30 a.m. on December 13, 2000, at

the U.S. International Trade

Commission Building, 500 E Street SW.,

Washington, DC. All persons have the

right to appear by counsel or in person,

to present information, and to be heard.

Persons wishing to appear at the public

hearing should file a letter with the

Secretary, United States International

Trade Commission, 500 E St., SW.,

Washington, DC 20436, not later than

the close of business (5:15 p.m.) on

November 27, 2000. In addition, persons

appearing should file prehearing briefs

(original and 14 copies) with the

Secretary by the close of business on

November 29, 2000. Posthearing briefs

should be filed with the Secretary by

close of business on December 21, 2000.

In the event that no requests to appear

at the hearing are received by the close

of business on November 27, 2000, the

hearing will be canceled. Any person

interested in attending the hearing as an

observer or non-participant may call the

Secretary to the Commission (202–205–

1816) after November 28, 2000 to

determine whether the hearing will be

held.

Written Submissions

In lieu of or in addition to appearing

at the public hearing, interested persons

are invited to submit written statements

concerning the investigation. Written

statements should be received by the

close of business on December 21, 2000.

Commercial or financial information

which a submitter desires the

Commission to treat as confidential

must be submitted on separate sheets of

paper, each clearly marked

‘‘Confidential Business Information’’ at

the top. All submissions requesting

confidential treatment must conform

with the requirements of section 201.6

of the Commission’s Rules of Practice

and Procedure (19 CFR 201.6). All

written submissions, except for

confidential business information, will

be made available for inspection by

interested persons. All submissions

should be addressed to the Secretary at

the Commission’s office in Washington,

D.C. The Commission’s rules do not

authorize filing of submissions with the

Secretary by facsimile or electronic

means. Hearing-impaired individuals

are advised that information on this

matter can be obtained by contacting

our TDD terminal on (202) 205–1810.

Issued: November 7, 2000.

By order of the Commission.

Donna R. Koehnke,

Secretary.

[FR Doc. 00–29072 Filed 11–13–00; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(I)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on February 3, 2000, Stepan

Company, Natural Products Department,

100 W. Hunter Avenue, Maywood, New

Jersey 07607, made application by

renewal to the Drug Enforcement

Administration to be registered as an

importer of coca leaves (9040), a basic

class of controlled substance listed in

Schedule II.

The firm plans to import the coca

leaves to manufacture bulk controlled

substance.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 is such

form as prescribed by 21 CFR 1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than (30 days from publication).

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: October 31, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–29036 Filed 11–13–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Federal Bureau of Investigation

DNA Advisory Board Meeting

Pursuant to the provisions of the

Federal Advisory Committee Act, notice